Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Dr. Neil Frankish

Adjunct Associate (Pharmacy)
      
Profile Photo

Dr. Neil Frankish

Adjunct Associate (Pharmacy)

 NFRNKISH@tcd.ie

 


  Applied information systems   Autoimmune and hypersensitivity diseases   Autoimmunity   Cardiovascular and molecular pharmacology   Chronic inflamation   Commercialisation of scientific research   Computerised clinical systems   Cytoskelton, cell division   Digestive Diseases & Disorders   Digestive System   Drug Development   Drug discovery, profiling, targeting   Gastrointestinal Diseases/Disorders   Immune System   Immune System Disorders   Immunoassays   Immunopathology   Immunosuppression   Inflammation   Inflammatory Bowel Disease   Information management   Pharmaceuticals   Pharmacology   Pharmacy   Transplantation immunology, tolerance and rejection
Project Title
 Effect of novel indanes on mast cell function
From
1/10/05
To
Summary
Novel indanes will be investigated on mast cell function and degrnaulation using harvested peritoneal mast cells, and mast cell lines such as RBL-3H3 and LAD2. Mediators studied will include histamine, cytokines etc.
Project Type
PH.D
Project Title
 Assessment of Novel Indanes as potential anti-asthmatic drugs
From
9/2005
To
6/2006
Summary
Novel indane compounds have been studied using mouse and rat bronchoalveolar lavage models of asthma, looking at cell recruitment into the lung, together with cytokine profiles, and their comparison with existing immunosupppression drugs.
Project Type
Ph.D
Project Title
 Studies on LFA-1 stimulated T-cell Motility
From
9/2004
To
Summary
A range of novel compounds are being studied on their effects on LFA-1 mediated HUT-78 T-cell motility.
Project Type
Ph.D
Project Title
 Novel indanes as potential therapies for auto-immune disease
From
1999
To
Summary
Novel indane compounds are being assessed in a variety of in vitro and in vivo models of auto-immune disease.
Funding Agency
Commercially funded
Project Type
Drug discovery
Project Title
 Effect of Extracts of Isodon & Bauhinia Species on Inflammation
From
10/2005
To
Summary
Extracts of several species of Isodon and Bauhinia are being studied on a range of innflammatory mediators and in vivo inflammatory models.
Project Type
Ph.D

Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
German Medium Medium Medium
Italian Basic Basic Basic
Portuguese Basic Basic Basic
Details Date From Date To
British Pharamacologigal Society 1979 Present
Zhang, T. and Scalabrino, G. and Frankish, N. and Sheridan, H., Bioactive indanes: Proof of concept study for enantioselective synthetic routes to ph46a, a new potential anti-inflammatory agent, Molecules, 23, (7), 2018, p1503-, Notes: [cited By 0], Journal Article, PUBLISHED  TARA - Full Text  DOI
Cumming, Graham; Zhang, Tao; Scalabrino, Gaia; Frankish, Neil; Sheridan, Helen, Investigation of the Stereoselective Synthesis of the Indane Dimer PH46A, a New Potential Anti-Inflammatory Agent , Organic Process Research & Development, 2018, p1972-1979 , Journal Article, PUBLISHED  DOI
Frankish, N.H. and McHale, B. and Sheridan, H., The indane diastereoisomers, PH2 and PH5: divergence between their effects in delayed-type hypersensitivity models and a model of colitis, Journal of Pharmacy and Pharmacology, 70, (1), 2018, p101-110 , Notes: [cited By 0], Journal Article, PUBLISHED  TARA - Full Text  DOI
Nazir I, Ur Rahman N, Alvi Z, Hafizur Rahman M, Sendker J, Zhang T, Frankish N, Sheridan H., Erratum: Antidiabetic Activities of an LC/MS Fingerprinted Aqueous Extract of Fagonia cretica L. in Preclinical Models., Planta medica, 2017, Journal Article, PUBLISHED  DOI
Imran Nazir, Nisar ur Rahman, Zunaira Alvi, M. Hafizur Rahman, Jandirk Sendker, Tao Zhang, Neil Frankish, Helen Sheridan, Antidiabetic Activities of an LC/MS Fingerprinted Aqueous Extract of Fagonia cretica L. in Preclinical Models*, Planta Medica, 83, 2017, p1-9 , Journal Article, PUBLISHED  DOI
N Frankish, H Sheridan -, 'Compounds for use in the treatment of immune related inflammatory disease', UPTO, 9,586,885, 2017, Venantius, Patent, GRANTED  URL
Neil Frankish and helen Sheridan, 'Compounds for use in the treatment of inflammatory Bowel Disease', USP, 9,586,885 B2, 2017, Venantius Ltd., Patent, GRANTED  URL
Tao Z, Paluch K, Scalabrino G, Frankish N, Healy AM, Sheridan H, Molecular structure studies of (1S,2S)-2-benzyl-2,3-dihydro-2-(1H-inden-2-yl)-1H-inden-1-ol, Journal of Molecular Structure, 2015, p286 - 299, Journal Article, PUBLISHED  TARA - Full Text  URL
N Frankish, H Sheridan -, 'Compounds for use in the Treatment of Autoimmune Inflammatory Disease', USPTO, 20,150,141,523,, 2015, Trino Therapeutics Ltd., Patent, GRANTED  URL
Frankish N, A study to assess the safety and tolerability of PH46A in healthy volunteers, to measure drug levels in these subjects and to determine the effect of food on the drug's absorption, 2014, -, Miscellaneous, PUBLISHED  DOI
  

Page 1 of 5
Neil Frankish and Helen Sheridan, Trino Therapeutics Ltd, 2011, Campus Company, PUBLISHED
E Passante, C Ehrhardt, H Sheridan, N Frankish, Toll-like receptors and RBL-2H3 mast cells, Inflamm Res, 37th Annual Meeting of the European Histamine Release Society, Stockholm, Sweden, 07-10/05/2008, 58, (S1), 2009, pp11-12 , Meeting Abstract, PUBLISHED
E Passante, C Ehrhardt, H Sheridan, N Frankish, Effect of novel indanes on the degranulation of rat basophilic leukemia mast cells (RBL-2H3), FASEB J, Experimental Biology Meeting 2007, Washington, DC, 28.04.-02.05.2007, 21, (5), 2007, pp574.9 , Meeting Abstract, PUBLISHED
E Passante, S Endter, MH Tindal, MR Pankratz, NH Frankish, C Ehrhardt, Albuterol is net absorbed across human bronchial epithelial cell layers in an enantiomer-dependent fashion, FASEB J, Experimental Biology Meeting 2007, Washington, DC, 28.04.-02.05.2007, 21, (5), 2007, pp881.2 , Meeting Abstract, PUBLISHED

  


Current research is largely concerned with finding novel drugs to treat auto-immune inflammatory disease such as inflammatory bowel disease multiple sclerosis and rheumatoid arthritis. Many of the classic immunosuppressive drugs available have a less than satisfactory toxicology profile. More recent monoclonal antibody anti-TNF therapy may be subject to auto-antibody formation and confer susceptibility to opportune infections. The research group concentrates on small molecule inhibitors, novel indane dimer derivatives, and their effects on several systems, including isolated T-cells and mast cells in culture and in vivo disease models. I have been responsible for directing a research program that took a potential drug candidate from its design in Chemdraw to clinical trial. This process included in vitro and in vivo validation studies, assessment in a variety of disease models together with the GLP toxicology and safety studies required for regulatory approval. In addition I was instrumental in designing the clinical trial respecting GCP guidelines, making the Clinical Trial Application to the MHRA and satisfying the Ethics Approval Board prior to the trial. During the clinical trial, I chaired the safety review committee and was responsible for approval for dose escalation in the human subjects. This is an achievement unparalleled in an Irish university.